There is an urgent need to identify effective strategies that can stop or reverse the inflammatory process that causes acute lung injury, ARDS, and multi-organ failure in COVID-19. Adaptive clinical trials with parallel enrollment to different arms each evaluating a rationally designed combination modality could provide the foundation for the accelerated identification of effective and safe multi-modality treatment algorithms for COVID-19 pneumonia. This article summarizes the insights and lessons learned from clinical immune-oncology trials as well as lung transplantation that are informing the clinical development of promising new strategies aimed at reducing the fatality rate in COVID-19.
All Keywords
【저자키워드】 COVID-19, acute respiratory distress syndrome, 2019-nCoV, acute lung injury, Cytokine release syndrome, systemic capillary leak, 【초록키워드】 Treatment, ARDS, clinical trial, Trial, Pneumonia, lung, Algorithm, Combination, Safe, Enrollment, Fatality rate, clinical development, multi-organ failure, inflammatory process, Arm, effective, identify, reducing, cause, accelerated, effective strategy, 【제목키워드】 clinical, lung transplantation, insight, Rate, Applying,
【저자키워드】 COVID-19, acute respiratory distress syndrome, 2019-nCoV, acute lung injury, Cytokine release syndrome, systemic capillary leak, 【초록키워드】 Treatment, ARDS, clinical trial, Trial, Pneumonia, lung, Algorithm, Combination, Safe, Enrollment, Fatality rate, clinical development, multi-organ failure, inflammatory process, Arm, effective, identify, reducing, cause, accelerated, effective strategy, 【제목키워드】 clinical, lung transplantation, insight, Rate, Applying,